Antitrust Chronicle® 2025
December 2025 - 2
This Chronicle brings together a collection of insightful articles from this year’s CRESSE conference, exploring key developments in competition law and policy.
December 2025 - 1
As talent becomes both the decisive input and the locus of competitive concern, agencies worldwide wrestle with whether hiring events should ever be treated as structural transactions—and, if so, when.
November 2025 - 2
In this Chronicle, our contributors explore the shifting frontier between intellectual property and competition law.
November 2025 - 1
Entertainment has always been where culture meets commerce — and where competition law reveals some of its most vivid tensions.
October 2025 - 2
This issue of the Chronicle brings together perspectives on how we think about consolidation, remedies, and the long-term fate of markets
October 2025 - 1
This edition of the Chronicle brings together a set of reflections on network effects, data, and the long shadow they cast over modern competition law.
September 2025 - 2
This CPI Antitrust Chronicle explores the renewed debate about how competition, market structure, and antitrust enforcement intersect with inflation.
September 2025 - 1
Market definition is perhaps the most important part of any antitrust analysis. This CPI Antitrust Chronicle takes a clear-eyed look at those questions.
August 2025 - 2
Following summer tradition, this edition of the Antitrust Chronicle compiles articles from members of the Chronicle’s Editorial Advisory Board.
August 2025 - 1
This annual edition of the Chronicle gathers contributions from leading voices within the state attorneys general community.
July 2025 - 2
The authors interrogate long-standing assumptions and emergent threats within agricultural markets—from seed monopolies to trade policy shocks,
July 2025 - 1
In this Chronicle, we examine the rise of “surveillance pricing”—a family of practices that use personal data to target, tailor, and sometimes manipulate the prices offered to consumers.
June 2025 - 1
This edition of the Chronicle gathers timely contributions, each grappling with a deceptively foundational question: What constitutes “harm” in competition law?
May 2025 - 2
This edition of the Chronicle gathers a set of contributions grappling with one of the most pressing economic governance questions of our time: how should competition policy respond to, align with, or constrain the resurgence of industrial policy?
May 2025 - 1
The present Chronicle addresses pressing antitrust and regulatory themes in the healthcare and pharmaceutical sectors across multiple jurisdictions.
April 2025 - 2
The authors featured in this edition of the CPI Antitrust Chronicle examine the intersection of enforcement theory, policy evolution, jurisdictional expansion, and economic realities, all of which ostensibly have a shared goal: to ensure competitive markets without stifling innovation.
April 2025 - 1
This edition of the Chronicle brings together a timely and thought-provoking collection of articles examining the evolving landscape of competition in the global and domestic airline industries.
March 2025 - 2
We are pleased to present our annual China Chronicle, presenting a curated collection of cutting-edge perspectives on competition law and policy in China
February 2025 - 2
Antitrust Chronicle February 2025 Self-Preferencing In this edition of the Chronicle, we explore the challenges posed by a relatively new concept in antitrust law — platform “self preferencing.” The conttributions bring analyses that not only delve into the economic and legal nuances of self preferencing but also offer innovative policy recommendations.
February 2025 - 1
Antitrust Chronicle: Supply Chains The legal landscape of antitrust enforcement and supply chain regulation is undergoing significant transformation, driven by geopolitical shifts, evolving trade policies, and the increasing dominance of technology firms.
January 2025 - 1
In this Chronicle, we delve into the complex and evolving world of Pharmacy Benefit Managers (“PBMs”), whose role in the healthcare and pharmaceutical industries has sparked intense debate.